Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804315 | 0.86 | PDK1 (0.54) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL1030263 | 0.85 | LMNA (0.74) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL18021884 | 0.83 | LMNA (0.58) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL12871700 | 0.82 | KMT2A (0.50) | KDM4ELMNAGAAALDH1A1MAPT | |
| SCHEMBL8140708 | 0.81 | KDM4E (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL7928023 | 0.81 | LMNA (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL1983314 | 0.81 | KDM4E (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL8806924 | 0.80 | CA12 (0.59) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL28991028 | 0.80 | KDM4E (0.46) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL9872617 | 0.80 | KDM4E (0.56) | KDM4ELMNAALOX12PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250393467-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-25 | — | — | US | disclosed |
| EP-2427434-B1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2331538-B1 | CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2687526-A1 | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8362035-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2010129451-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | KDM4E 3478/4885LMNA 3920/4885ALOX12 4366/4885 |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | KDM4E 3478/4885LMNA 3920/4885ALOX12 4366/4885 |
| US-20250393467-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OXSR1, EPOR | KDM4E 4234/4885LMNA 1982/4885ALOX12 628/4885 |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | KDM4E 2953/4885LMNA 1366/4885ALOX12 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.